An 82-year-old lady with hypertension and hyperlipidaemia presented with 2 weeks’ history of increasing breathing difficulty. She had flu-like illness 2 weeks ago with some residual dry cough. Physical examination showed low-grade fever of 37.8°C with mildly elevated jugular venous pressure and mild pedal oedema. There was no obvious murmur, and chest auscultation revealed bilateral basal crepitations. Her blood pressure was 130/80 mm Hg. She required oxygen 1 L/min to maintain blood oxygen saturation level (SpO2) of 94 percent.
This is the case of a 77-year-old man with a history of pulmonary tuberculosis (TB). In September 2015, he was admitted to a regional hospital in Hong Kong due to fever and shortness of breath, and was diagnosed with pneumonia, the fourth episode in his life.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Respirology - Malaysia digital copy today!
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.